Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial

IMPORTANCE: Rituximab is a third-line option for refractory generalized myasthenia gravis (MG) based on empirical evidence, but its effect in new-onset disease is unknown. OBJECTIVE: To investigate the efficacy and safety of rituximab compared with placebo as an add-on to standard of care for MG. DE...

Descripción completa

Detalles Bibliográficos
Autores principales: Piehl, Fredrik, Eriksson-Dufva, Ann, Budzianowska, Anna, Feresiadou, Amalia, Hansson, William, Hietala, Max Albert, Håkansson, Irene, Johansson, Rune, Jons, Daniel, Kmezic, Ivan, Lindberg, Christopher, Lindh, Jonas, Lundin, Fredrik, Nygren, Ingela, Punga, Anna Rostedt, Press, Rayomand, Samuelsson, Kristin, Sundström, Peter, Wickberg, Oskar, Brauner, Susanna, Frisell, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486640/
https://www.ncbi.nlm.nih.gov/pubmed/36121672
http://dx.doi.org/10.1001/jamaneurol.2022.2887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486640/
https://www.ncbi.nlm.nih.gov/pubmed/36121672
http://dx.doi.org/10.1001/jamaneurol.2022.2887

Ejemplares similares